Epidemiological profile and treatment patterns in ulcerative colitis

• Grant number: 19/08786-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): October 01, 2019
• Effective date (End): September 30, 2020
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Ligia Yukie Sassaki
• Grantee: Amanda Moraes Tamburrino
• Host Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Ulcerative colitis (UC) is a chronic and idiopathic disease characterized by continual and circunferential inflammation of the colon and rectum mucosa manifested by bloody diarrhea, abdominal pain, tenesmus, urgency and fecal incontinence. The increase in the prevalence of UC in recent years has been followed by the growth of the arsenal of therapeutic agents for the maintenance of disease remission, however, a portion of the patients remains refractory to the currently available therapies. Thus, it is important to know the epidemiological profile of the patients, as well as the evolution of the disease, the treatment patterns and the clinical and endoscopic responses to the treatments, to evaluate which therapies are more effective and allow a better quality of life for the patients. Objectives: To describe the epidemiological profile of the patients and to evaluate the evolution of the disease, the treatment patterns and the response rates to the treatments. Methodology: A retrospective observational study will be performed with an evaluation of the clinical and endoscopic evolution of individuals with UC. Data collection will be performed through consultation of the electronic medical record system. Clinical and socio-demographic variables will be analyzed. The UC activity will be analyzed using the Mayo Score. The clinical response will be based on improved symptoms. Clinical remission will be defined as absence of diarrhea and absence of bleeding in the stool. Endoscopic response will be based on the endoscopic Mayo Score 0 or 1. Drug treatment with sulfasalazine, mesalazine, corticosteroids, azathioprine, infliximab, adalimumab, vedolizumab or other medication will be evaluated. The rates of hospitalization, colectomy surgery and death will be evaluated. Statistics: descriptive and association tests.